LQDA
$36.86
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Recent News
Why Liquidia (LQDA) Is Down 5.1% After Swing to Profit and $125 Million Shelf Filings
In March 2026, Liquidia Corporation reported that fourth-quarter 2025 revenue rose to US$92.02 million from US$2.92 million a year earlier, swinging from a net loss to net income of US$14.56 million and positive earnings per share. On the same day, the company also filed multiple shelf registrations covering common and preferred stock, debt, warrants, and ESOP-related common share offerings totaling over US$125 million, highlighting an intention to access fresh capital alongside its...
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia
Biotech momentum in 2026 spotlights companies like Liquidia and ANI Pharmaceuticals as pipeline innovation, drug demand and rising M&A activity drive sector interest.
4 Biotech Stocks to Watch for Potential Upside in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart
Dave Inc. delivers digital banking and personal finance tools designed to offer alternatives to traditional banking platforms.
Best Momentum Stocks to Buy for March 10th
STRL, LQDA and NWPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 10th, 2026.